Last week, AstraZeneca announced the submission of a marketing authorisation application to the European Medicines Agency (EMEA) for its oral anti-cancer drug, gefitinib (IRESSA™) as a treatment for locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have been pre-treated with platinum-containing chemotherapy. The application was based on data from the Phase [...]
Entries Tagged as 'lung'
AZ and Iressa attempting a comeback in lung cancer?
May 9th, 2008 · No Comments · cancer, company news, competitive intelligence, lung, market intelligence, market trends, oncology
Tags: